Zheng, Y., Wang, Y. and Zhang, X. (2025) ⁶⁸Ga-FAPI-04 PET/CT for the Assessment of Light-Chain Cardiac Amyloidosis: A Promising Risk-Stratification Imaging Modality. Current Cardiology Reports, 27, Article No. 83.
https://doi.org/10.1007/s11886-025-02230-x

has been cited by the following article:

• TITLE: Research Progress in Imaging of Cardiac Amyloidosis

  AUTHORS: Chengling Huang, Ming Wen

  KEYWORDS: Cardiac Amyloidosis, Echocardiography, CT, MR, Nuclear Medicine

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.7, July 23, 2025

  ABSTRACT: Cardiac amyloidosis (CA) is a progressive disease characterized by extracellular deposition of misfolded proteins, leading to myocardial dysfunction and poor prognosis. Early and accurate diagnosis remains challenging due to nonspecific clinical presentations. This review highlights advancements in multimodality imaging for CA: echocardiography, as a noninvasive, accessible, and cost-effective initial screening tool, enhances diagnostic sensitivity through characteristic strain patterns (e.g., “apical sparing”); computed tomography (CT) quantifies amyloid burden via extracellular volume fraction (CT-ECV), particularly valuable for patients with contraindications to MRI; cardiac magnetic resonance (CMR) excels in phenotyping and prognostic stratification using multiparametric techniques (e.g., late gadolinium enhancement and T1 mapping); and nuclear medicine (SPECT/PET) enables noninvasive subtyping and therapy monitoring through targeted tracers (e.g., ⁹⁹ᵐTc-PYP and ¹¹C-PiB). The integration of multimodal imaging significantly improves early diagnosis, subtype differentiation, and prognostic evaluation in CA, providing a foundation for personalized treatment strategies.